(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

ASCO 2025 BULLSEYE trial, Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy, androgen deprivation therapy (ADT), 177Lu-PSMA-617, PSMAddition.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer.

SNMMI 2025, PROSTATE CANCER, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Artificial Intelligence-based Risk Score for Prostate Cancer on PSMA PET/CT.

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured an alpha and other radionuclides session and a presentation by Dr. Alfred Morgenstern discussing 212 Pb-PSMA versus 225 Ac-PSMA. Dr.

UroToday's exclusive Video Lecture content covering mCRPC Treatment.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.